Specialized testing
Delivering value beyond the test result
Our commitment to improving patient outcomes propels the development of clinically impactful, patient-focused testing. Supported by clinical physicians and laboratory scientists with unmatched experience and expertise, our assays — several of which are unavailable elsewhere — deliver actionable answers that improve patient lives.
Our data-driven, evidence-based tests provide actionable answers for patients that clarify each patient’s unique healthcare journey.
Specialty testing menu
Collaborations that power innovation
We relentlessly innovate on behalf of patients to build tests of the future to help physicians impact more lives. Mayo Clinic Laboratories scientists and physicians are leaders in their fields and at the forefront of translating new ideas into meaningful solutions. Through groundbreaking collaborations with healthcare companies and diagnostics leaders, we simplify access to new and advanced laboratory tests.
Commitment to education
The exchange of knowledge is a founding principle at Mayo Clinic. In this tradition, we provide a wide range of education offerings and outreach consultation to help you drive continual improvement.
- Regionally based clinical specialists help guide best practices through physician education.
- Access to Mayo Clinic Laboratories' education offerings and Insight articles.
- Many courses offer CME credits.
- Online trainings are available, such as “Dangerous Goods Shipping,” and include printable certificates.
News and updates
The latest
Genome-wide methylation profiling is transforming the way clinicians approach brain tumor diagnosis. By analyzing epigenetic patterns across the genome, this advanced testing method provides a new level of precision, helping resolve ambiguous cases, reduce diagnostic variability, and support more confident clinical decision-making in complex CNS tumors.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to discuss Protecting Access to Medicare Act (PAMA) reform and recent reports about the New World screwworm. Dr. Morice also shares insights on building an innovation strategy that delivers meaningful organizational value.
Genome-wide methylation profiling is transforming the way clinicians approach brain tumor diagnosis. By analyzing epigenetic patterns across the genome, this advanced testing method provides a new level of precision, helping resolve ambiguous cases, reduce diagnostic variability, and support more confident clinical decision-making in complex CNS tumors.
Learn how our suite of testing reveals the cause of bile acid-induced diarrhea in a 66-year-old woman.
Learn how GFAP testing is emerging as a biomarker to support diagnosis, monitoring, and prognosis in neurological diseases.
Register now–Oct. 13, 2026 Review key federal legislative and regulatory developments affecting clinical laboratories.
Discuss ways to increase transparency in the workplace to maintain a safe, honest working relationship between colleagues.
Join us at the 2026 Mayo Clinic Classical Hematology Conference: Nonmalignant Hematology and Bleeding and Thrombotic Disorders, where innovation, collaboration, and expertise come together to advance the field of hematology.
Find out how ileal resection accelerates bile acid malabsorption symptoms in an 80-year-old woman with Crohn’s disease.
In this episode of the “Leveraging the Laboratory” podcast, host Jane Hermansen, outreach manager at Mayo Clinic Laboratories, is joined by colleagues Wendy Daigle and Ellen Dijkman Dulkes to discuss how laboratory outreach programs can use metrics to drive performance, strengthen client relationships, and support long-term growth.
In the second quarter of 2026, Mayo Clinic Laboratories expanded its test catalog with several innovative new tests.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to discuss the Protecting Access to Medicare Act (PAMA) and a recent Cyclospora outbreak making headlines. Later, Dr. Pritt welcomes Juliana Perez Botero, M.D., a Mayo Clinic hematologist, to explore innovative testing approaches for bleeding disorders.
As innovation in clinical diagnostics accelerates, collaboration is becoming increasingly essential to ensure new tools reach the clinicians and patients who need them most. Mary Jo Williamson, chief administrative officer at Mayo Clinic Laboratories, discusses how a strategic approach to collaboration is helping build a more connected diagnostic ecosystem and enabling more comprehensive care.